Page last updated: 2024-08-26

paxilline and gentian violet

paxilline has been researched along with gentian violet in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Donato, NJ; Johnson, FM; Saigal, B; Talpaz, M	1

Other Studies

1 other study(ies) available for paxilline and gentian violet

Article	Year
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 1 Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Collagen; Crk-Associated Substrate Protein; Dasatinib; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Focal Adhesion Protein-Tyrosine Kinases; G1 Phase; Gentian Violet; Head and Neck Neoplasms; Humans; Immunoprecipitation; Inhibitory Concentration 50; Laminin; Lung Neoplasms; Neoplasm Invasiveness; Neovascularization, Pathologic; Paxillin; Phosphorylation; Protein-Tyrosine Kinases; Proteoglycans; Pyrimidines; Retinoblastoma Protein; S Phase; Signal Transduction; src-Family Kinases; Thiazoles; Time Factors; Trypan Blue	2005

Article

Year

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 1

Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Collagen; Crk-Associated Substrate Protein; Dasatinib; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Focal Adhesion Protein-Tyrosine Kinases; G1 Phase; Gentian Violet; Head and Neck Neoplasms; Humans; Immunoprecipitation; Inhibitory Concentration 50; Laminin; Lung Neoplasms; Neoplasm Invasiveness; Neovascularization, Pathologic; Paxillin; Phosphorylation; Protein-Tyrosine Kinases; Proteoglycans; Pyrimidines; Retinoblastoma Protein; S Phase; Signal Transduction; src-Family Kinases; Thiazoles; Time Factors; Trypan Blue

2005